NCL’s first fund is based at Discovery Park and invests primarily in a diverse range of biotech and environmental technologies:

Emerging clinical stage biotechnology business developing a revolutionary treatment for asthma

 

Specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health

 

Clinical stage Immuno-Oncology business with pipeline of innovate cell therapies

 

Biotech company developing novel immunotherapies to combat cancer and infectious disease

 

The World’s first real time airborne asbestos Alert

 

Creating beautiful office furniture from waste cardboard

 

Clean low cost drying technologies

 

Principal advisor to seed round

 

NCL also manage some existing equity investments of one of our main local authority investors:

Sold to Sienna Biopharmaceuticals – 2016

 

Medical grade iPad case

 

Molecular detection technology providing unprecedented levels of sensitivity

 

Accessible digital health records for clinicians and patients

 

Real time sentiment data analytics for the financial markets

 

Non-invasive skin cancer diagnostic

 

Targeted venom discovery arrays for pharma and cosmetic use

 

Efficient and low emission vehicle exhaust system

 

Pharmaceutical consultancy and drug discovery platform

 

Compact and wearable cough monitor for asthma and COPD

 

NCL have recently launched their new Life Science fund.  Details can be provided by the company upon request.

smenews-winner